Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition and administration thereof

a technology of pharmaceutical compositions and compositions, applied in the field of pharmaceutical compositions, can solve the problems of imbalance in ion and fluid transport, no cure, and individuals with two copies of the cf associated gene suffering from the debilitating and fatal effects of cf, and achieve the effects of enhancing its visual appeal, taste, and scen

Inactive Publication Date: 2010-03-25
VERTEX PHARMA INC
View PDF3 Cites 163 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0027]Such pharmaceutical compositions can optionally comprise one or more colorants, fragrances, and / or flavors to enhance its visual appeal, taste, and scent.

Problems solved by technology

Despite progress in the treatment of CF, there is no cure.
In contrast, individuals with two copies of the CF associated gene suffer from the debilitating and fatal effects of CF, including chronic lung disease.
In patients with CF, mutations in CFTR endogenously expressed in respiratory epithelia leads to reduced apical anion secretion causing an imbalance in ion and fluid transport.
The resulting decrease in anion transport contributes to enhanced mucus accumulation in the lung and the accompanying microbial infections that ultimately cause death in CF patients.
In addition to respiratory disease, CF patients typically suffer from gastrointestinal problems and pancreatic insufficiency that, if left untreated, results in death.
This results in the inability of the mutant protein to exit the ER, and traffic to the plasma membrane.
In addition to impaired trafficking, the mutation results in defective channel gating.
Together, the reduced number of channels in the membrane and the defective gating lead to reduced anion transport across epithelia leading to defective ion and fluid transport.
As discussed above, it is believed that the deletion of residue 508 in ΔF508-CFTR prevents the nascent protein from folding correctly, resulting in the inability of this mutant protein to exit the ER, and traffic to the plasma membrane.
As a result, insufficient amounts of the mature protein are present at the plasma membrane and chloride transport within epithelial tissues is significantly reduced.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition and administration thereof
  • Pharmaceutical composition and administration thereof
  • Pharmaceutical composition and administration thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Exemplary Tablet 1 (Formulated to have 25 mg of Compound 1)

[0699]A batch of round core ⅜″ tablets was formulated to have approximately 25 mg of Compound 1 per tablet using the amounts of ingredients recited in Table 1, below.

TABLE 1Ingredients for Exemplary Tablet 1.Percent DoseDoseBatchTablet Formulation% Wt. / Wt.(mg)(g)Intermediate A15.29%51.23512.5Microcrystalline cellulose35.00%117.251172Lactose43.85%146.001460Sodium croscarmellose5.000%16.75167.5SLS0.500%1.67516.75Colloidal silicon dioxide0.125%0.41884.188Magnesium stearate0.50%1.67516.75Total100%3353350

[0700]Intermediate A, microcrystalline cellulose (FMC MCC Avicel® PH102, commercially available from FMC BioPolymer Corporation of Philadelphia, Pa.), lactose (Foremost FastFlo® Lactose #316 commercially available from Foremost Farms USA of Baraboo, Wis.), sodium croscarmellose (FMC Ac-Di-Sol®, commercially available from FMC BioPolymer Corporation of Philadelphia, Pa.), SLS, and colloidal silicon dioxide (Cabot Cab-O-Sil® M-5P F...

example 2

Exemplary Tablet 2 (Formulated to have 50 mg of Compound 1)

[0710]A batch of round core ⅜″ tablets was formulated to have about 50 mg of Compound 1 per tablet using the amounts of ingredients recited in Table 2, below.

TABLE 2Ingredients for Exemplary Tablet 2.Percent DoseDoseBatchTablet Formulation% Wt. / Wt.(mg)(g)Intermediate A30.60%102.501025.0Microcrystalline cellulose25.00%83.75837.5Lactose38.28%128.231282.3Sodium croscarmellose5.000%16.75167.5SLS0.500%1.67516.75Colloidal silicon dioxide0.125%0.41884.188Magnesium stearate0.50%1.67516.75Total100%3353350

[0711]Intermediate A, microcrystalline cellulose, lactose, sodium croscarmellose, SLS, and colloidal silicon dioxide were sieved through a 20 mesh screen to remove lumps, and each of the sieved ingredients was added to a 16 quart V-blender in the following order:

[0712]1) lactose;

[0713]2) SLS;

[0714]3) sodium croscarmellose;

[0715]4) colloidal silicon dioxide;

[0716]5) Intermediate A; and

[0717]6) microcrystalline cellulose PH101

[0718]The...

example 3

Exemplary Tablet 3 (Formulated with PVP / VA Polymer to have 150 mg of Compound 1)

[0720]A batch of caplet-shaped tablets was formulated to have about 150 mg of Compound 1 per tablet using the amounts of ingredients recited in Table 3, below.

TABLE 3Ingredients for Exemplary Tablet 3.Percent DoseDoseBatchTablet Formulation% Wt. / Wt.(mg)(g)Intermediate B40.000%187.50240.00Microcrystalline cellulose27.063%126.86162.38Lactose27.063%126.86162.38Sodium croscarmellose3.000%14.0618.00SLS0.500%2.343.00Colloidal silicon dioxide1.000%4.696.00Coloring0.375%1.762.25Magnesium stearate1.000%4.696.00Total100%469600

[0721]A glidant blend of colloidal silicon dioxide (Cabot Cab-O-Sil® M-5P Fumed Silicon Dioxide) and SLS was produced by hand mixing these two ingredients, in the amounts given in Table 3, and filtering the resulting mix through a 70 mesh screen sieve. A color blend of coloring (Colorcon Blue #1 Aluminum Lake #5516) and sodium croscarmellose (FMC Ac-Di-Sol®) was produced by hand mixing these ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Timeaaaaaaaaaa
Massaaaaaaaaaa
Login to View More

Abstract

The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This Application claims priority to U.S. Ser. No. 61 / 088,704 filed on Aug. 13, 2008, U.S. Ser. No. 61 / 088,801, filed on Aug. 14, 2008, U.S. Ser. No. 61 / 090,096, filed on Aug. 19, 2008, U.S. Ser. No. 61 / 146,163, filed on Jan. 21, 2009, U.S. Ser. No. 61 / 181,527, filed on May 27, 2009, and U.S. Ser. No. 61 / 183,345, filed on Jun. 2, 2009, each of which is incorporated by reference in their entirety.FIELD OF THE INVENTION[0002]The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, and methods of manufacturing and administering pharmaceutical compositions comprising N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide.BACKGROUND[0003]Cystic fibrosis (CF) is a recessive genetic disease that affects approximately 30,000 children and adults in the United States and approximately 30,000 c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/28A61K31/47A61K9/42A61K9/44A61P3/00A61P19/10
CPCA61K9/1635A61K9/1652A61K9/2054A61K9/282A61K9/284A61K9/2009A61K9/2013A61K9/2018A61K9/2027A61K31/47A61K31/44A61P11/00A61P11/08A61P19/00A61P19/08A61P19/10A61P29/00A61P3/00A61P43/00A61K2300/00A61K9/14A61K9/0053A61K9/28
Inventor ROWE, WILLIAMHURTER, PATRICIAYOUNG, CHRISTOPHERDINEHART, KIRKVERWIJS, MARINUS JACOBUSOVERHOFF, KIRKGROOTENHUIS, PETER D.J.BOTFIELD, MARTYNGROSSI, ALFREDO
Owner VERTEX PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com